Some cookies are essential to the running of the website, while others (analytics) help us to make improvements. We also incorporate functionality from other websites, such as video, social media feeds and ReachDeck (text-to-speech and translations services) which may set cookies. More on how we use cookies
This website uses text-to-speech software called ReachDeck to read and / or translate its content. To use ReachDeck, you must allow ReachDeck cookies; the ReachDeck icon will then appear at the bottom right of your screen.
You can find out more about how ReachDeck uses cookies or change your cookie preferences at any time by going to our cookies page.
Allow ReachDeck cookies Do not use ReachDeck
Please find service updates and current visiting rules in our COVID-19 section.
This site is best viewed with a modern browser. You appear to be using an old version of Internet Explorer.
Variations in monitoring requirements may occur and this should be read in conjunction with:
If you have any concerns or queries regarding your patient's blood monitoring please contact us.
If you advise a patient to withhold medication please let us know for our records:
Contact us
For details of standard drug monitoring for patients on long-term treatment please refer to:
Oxfordshire CCG Shared Care Guidance 'Rheumatology Monitoring General Guidance'.
For specific advice on methotrexate use please see:
British Society for Rheumatology guidelines.
For information on monitoring of biologics in children and adolescents please see: